Nalbuphine ER: Phase I started

Trevi began an open-label, dose-escalation Phase I trial to evaluate oral Nalbuphine ER in 12 patients with end-stage renal disease and 8 healthy volunteers. Trevi plans to begin a Phase II/III trial ...